Co-amoxiclav is NOT recommended for hidradenitis suppurativa
Amoxicillin-clavulanate (co-amoxiclav) is not supported by current evidence-based guidelines for HS treatment and should not be used. The North American guidelines do not mention co-amoxiclav as a treatment option, and the established antibiotic regimens for HS are entirely different 1.
Why Co-amoxiclav is Not Appropriate
The FDA-approved indications for amoxicillin-clavulanate include respiratory infections, otitis media, sinusitis, skin/soft tissue infections caused by beta-lactamase-producing organisms, and urinary tract infections 2. Hidradenitis suppurativa is not among these indications, and the bacterial flora in HS lesions differs substantially from those targeted by this antibiotic.
The Bacterial Profile Problem
HS lesions harbor a polymorphous anaerobic flora including actinomycetes and milleri group streptococci 3. Research shows high resistance rates to commonly used antibiotics in HS patients, with concerning resistance patterns that would likely extend to amoxicillin-based regimens 4. The bacterial spectrum in HS does not align with co-amoxiclav's coverage profile.
What You Should Use Instead
For mild-to-moderate HS, use oral tetracyclines as first-line therapy 5. The evidence-based antibiotic options are:
First-line systemic antibiotics:
- Tetracyclines (doxycycline or minocycline) - now recognized as effective alternatives 5
- Clindamycin 300mg + Rifampin 300mg twice daily - the traditional combination regimen 1
For severe inflammatory flares:
- Intravenous clindamycin for 5 days can shorten the duration of systemic antibiotic therapy 5
Topical options for localized disease:
- Clindamycin 1% solution - the only topical antibiotic with trial data, though it reduces pustules but not inflammatory nodules 1
Critical Caveat
Antibiotic resistance is a major concern in HS. Studies show resistance rates of 65.7% to clindamycin, 69.3% to rifampicin, and 70% to penicillin in HS bacterial cultures 4. This underscores why empiric use of non-guideline antibiotics like co-amoxiclav is problematic - you're using an agent without evidence of efficacy while potentially contributing to resistance.
The Treatment Algorithm
Base your antibiotic choice on disease severity using the IHS4 classification 5:
- Mild inflammatory HS: Oral tetracyclines
- Moderate-to-severe inflammatory HS: Consider clindamycin/rifampicin combination OR tetracyclines, with biologics (adalimumab, secukinumab, bimekizumab) for inadequate response
- Acute severe flares: 5-day IV clindamycin followed by oral regimen
- Predominantly non-inflammatory disease: Surgical intervention rather than antibiotics
The key principle: HS requires specific antibiotic regimens with documented efficacy, not broad-spectrum agents used for typical skin infections. Co-amoxiclav falls into the latter category and lacks any supporting data for HS management.